Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.

Enzyme replacement therapy Laronidase Liposome Nasal route mucopolysaccharidosis type I

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 04 04 2024
revised: 14 06 2024
accepted: 15 06 2024
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 19 6 2024
Statut: aheadofprint

Résumé

Mucopolysaccharidosis type I (MPS I) is caused by lack of the lysosomal enzyme α-L-iduronidase (IDUA), responsible for the degradation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate, leading to multisystemic signs and symptoms. Enzyme replacement therapy (ERT) is a treatment that consists of weekly intravenous administrations of laronidase, a recombinant version of IDUA. However, ERT have limited access to certain tissues, such as bone, cartilage, and brain, and laronidase fails to trespass the BBB. In this sense, this study reports the development and characterization of laronidase-loaded liposomes for the treatment of MPS I mice. Liposomal complexes were obtained by the thin film formation method followed by microfluidization. The main characterization results showed vesicle size of 103.0 ± 3.3 nm, monodisperse populations of vesicles, zeta potential around + 30.0 ± 2.1 mV, and mucoadhesion strength of 5.69 ± 0.14 mN. Treatment of MPS I mouse fibroblasts showed significant increase in enzyme activity. Nasal administration of complexes to MPS I mice resulted in significant increase in laronidase activity in the brain cortex, heart, lungs, kidneys, eyes, and serum. The overall results demonstrate the feasibility of nasal administration of laronidase-loaded liposomes to deliver enzyme in difficult-to-reach tissues, circumventing ERT issues and bringing hope as a potential treatment for MPS I.

Identifiants

pubmed: 38897489
pii: S0378-5173(24)00589-1
doi: 10.1016/j.ijpharm.2024.124355
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124355

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Roselena Silvestri Schuh has patent #BR 1020200049887 pending to No. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Roselena Silvestri Schuh (RS)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil; Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address: roselena.schuh@ufrgs.br.

Eduarda Piovesan Franceschi (EP)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil.

Bruna Brazeiro Brum (BB)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil; Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

Flávia Nathiely Silveira Fachel (FNS)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil.

Édina Poletto (É)

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.

Luisa Natália Pimentel Vera (LNP)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.

Hallana Souza Santos (HS)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

Bruna Medeiros-Neves (B)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil.

Vinicius Monteagudo de Barros (V)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil.

Ana Helena da Rosa Paz (A)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

Guilherme Baldo (G)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Postgraduate Program in Genetics and Molecular Biology, UFRGS, Porto Alegre, RS, Brazil.

Ursula Matte (U)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Postgraduate Program in Genetics and Molecular Biology, UFRGS, Porto Alegre, RS, Brazil.

Roberto Giugliani (R)

Cells, Tissues and Genes, Experimental Research Centre, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Postgraduate Program in Genetics and Molecular Biology, UFRGS, Porto Alegre, RS, Brazil.

Helder Ferreira Teixeira (H)

Postgraduate Program in Pharmaceutical Sciences, UFRGS, Porto Alegre, RS, Brazil.

Classifications MeSH